News Category
Oncotelic Therapeutics will present its AI-enabled PDAOAI platform and international IP strategy at a key industry summit, highlighting a potential sh...
VERAXA Biotech AG is advancing a diversified oncology pipeline with innovative antibody-based therapeutics, positioning itself in the fast-growing glo...
Quantum BioPharma announced the completion of Phase 1 clinical studies for LUCID-MS, a therapy targeting myelin repair in multiple sclerosis, and subm...
Redwood AI Corp. is developing a proprietary AI platform for drug discovery, synthesis planning, and chemical analysis, targeting pharmaceutical, defe...
TransCode Therapeutics announced positive Phase 1a trial results for its microRNA-10b inhibitor TTX-MC138, showing safety and durable disease stabiliz...
iOrganBio has appointed Zhiping Pang, M.D., Ph.D., a renowned expert in human neuron biology and neuropsychiatric disorders, to its Scientific Advisor...
Quantum BioPharma Ltd. is progressing a clinical-stage multiple sclerosis program targeting demyelination, with Phase 1 safety studies completed and a...
TransCode Therapeutics has launched a Phase 2a clinical trial of its lead candidate TTX-MC138 in colorectal cancer patients with minimal residual dise...
Redwood AI Corp. partners with Resilience Biosciences to apply AI-driven computational chemistry for non-opioid therapeutic development, aiming to spe...
NanoViricides announces that its broad-spectrum antiviral candidate NV-387 could be evaluated for the Bundibugyo Ebola outbreak, offering potential ad...
Oncotelic Therapeutics (OTLC) has integrated 28 million scientific abstracts into its proprietary PDAOAI platform, positioning itself to compete with ...
New research published in Science and Technology of Advanced Materials reveals that graphene quantum dots can interfere with the aggregation of α-synu...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn improved survival and reduced copper burden in Wilson’s disease mo...
Sino Biological introduces XPressMAX, a cell-free protein synthesis kit that synthesizes proteins in three hours, enabling rapid AI-driven high-throug...
NanoViricides highlights its oral antiviral candidate NV-387 as a potential pandemic preparedness tool for Ebola and related filoviruses, citing its m...
Lantern Pharma reported a 47% reduction in R&D spending while advancing key clinical trials and launching its AI drug development platform withZeta.ai...
LIXTE Biotechnology announced first-quarter 2026 results showing advancement of its PP2A inhibitor LB-100 in ovarian cancer trials and growth at its L...
Kairos Pharma receives the 2026 GHP Magazine Healthcare & Pharmaceutical Award for its innovative work in developing cancer therapeutics that target d...
SureNano Science Ltd. is advancing its triple agonist peptide GEP-44 through subsidiary GlucaPharm Inc., targeting the rapidly expanding obesity and m...
NanoViricides points to its clinical-stage antiviral candidate NV-387 as a potential broad-spectrum therapeutic for emerging viral threats after a rec...
Lantern Pharma announced expansion plans for its withZeta.ai platform, including ZetaSwarm and ZetaOmics, to enhance AI-driven oncology research and d...
Oragenics signs a letter of intent to license Sigyn Therapeutics' CardioDialysis blood purification technology to develop a dual-modality treatment fo...
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provis...
Lantern Pharma announced the expansion of its predictBBB platform into a Large Quantitative Model, providing researchers with a real-time molecular in...
Oncotelic Therapeutics introduces PDAOAI, an evidence-interrogation platform indexing over 125,000 PubMed abstracts on TGF-β signaling to generate tra...
LIXTE Biotechnology is developing LB-100, a first-in-class PP2A inhibitor that enhances chemotherapy and radiation efficacy while reducing side effect...
LIXTE Biotechnology is developing LB-100, a small-molecule PP2A inhibitor that enhances chemotherapy and radiation efficacy while reducing side effect...
Lantern Pharma (NASDAQ: LTRN) will showcase its multi-agentic AI platform withZeta.ai in a live public demonstration on April 30, 2026, highlighting i...
SureNano Science Ltd. initiates IND-enabling GLP toxicology for GEP-44 targeting diabetes and obesity, and expands investor outreach via IBN.
Oncotelic Therapeutics is highlighted in a BioMedWire editorial discussing how advancing drug pipelines are reshaping biotech valuations, with its AI-...
